Cross-Border Success: Jinxin Fertility’s Revenue Surges 22% Driven by US-China "Dual-Corridor" Strategy
Jinxin Fertility (HK: 1951) released its preliminary FY2025 earnings today, reporting a 22% year-on-year revenue increase. The growth was primarily driven by their "HRC Fertility" US operations, which saw a 40% spike in Chinese patients traveling for PGT-A testing and surrogacy services, now that travel restrictions have fully normalized.
Policy Thaw: Two Chinese Provinces Pilot Oocyte Cryo preservation for Non-Married Women with Medical Indications
Breaking news from the National Health Commission (NHC) briefing this morning: A limited pilot program has been approved for Sichuan and Guangdong.